News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuation
Tasly Biopharma (SHA: 600535) of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange.
Read
Week In Review: Suzhou Innovent Files For HK IPO -- $500 Million Raise Rumored
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.
Read
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios in a deal worth up to $424 million. CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia (AML) and cholangiocarcinoma.
Read
Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's top five plasma-based biopharmas (. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding.
Read
Week In Review: Mevion Medical Of Boston Closes $150 Million Financing From China Investors
Mevion Medical Systems, a Boston area maker of proton therapy machines, closed a $150 million financing led by YuanMing Capital with participation by other China-based private equity investors.
Read
Week In Review: Hua Medicine Approved For $200 Million Hong Kong IPO
Hua Medicine, a Beijing biopharma, announced its IPO application was accepted by the Hong Kong exchange. According to rumors, the company hopes to raise $200 million in the offering.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

LATEST ACTIVITY

ChinaBio® Today
Week In Review: Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuation $MRK $MRK $NVS $IBIO https://t.co/V2A2aoz9tR less
ChinaBio® Today
Week In Review: Suzhou Innovent Files For HK IPO -- $500 Million Raise Rumored $LLY $LLY $SNY $SVA $BABA $ATNX https://t.co/iu1KXZq1Hx less
ChinaBio® Today
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal $AGIO $AGIO $LGND $NVS $ZLAB https://t.co/72JHRwpVTJ less
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications